Article
HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil
10 Mar 2009
Abstract excerpt
Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse, suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
